Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Table 1 Characteristics of the selected patients at admission (n = 12)

Variables	Values
Age, yrs	68.8 ± 6.9
Gender, male/female	9/3
Types of NSCLC, adeno/squamous/NOS	8/3/1
Types of ICI, nivolumab/pembrolizumab	7/5
Duration of ICI use, mo	5.0 ± 4.1
mMRC dyspnea grade, 0/1/2/3/4	3/2/5/1/1
Grade of pneumonitis, 1/2/3/4	2/7/3/0

Values are expressed as mean ± standard deviation or by the actual number
Grade of pneumonitis was assessed according to CTCAE v5.0
CTCAE, Common Terminology Criteria for Adverse Events; ICI, immune checkpoint inhibitor; mMRC, modified Medical Research Council; NSCLC, non-small cell lung cancer; NOS, not otherwise specified

ISSN: 1471-2466